Galderma | Jotup

Leading Payments Platform Receives Significant Growth Equity Investment from Questa Capital

Retrieved on:

Tuesday, February 13, 2024

The growth capital will be used primarily for accelerating sales and marketing, developing new commercial partnerships, and launching new product initiatives.

Key Points:

The growth capital will be used primarily for accelerating sales and marketing, developing new commercial partnerships, and launching new product initiatives.
Founded in 2017, PatientFi has steadily grown into a leading point of care payments platform to increase patient affordability and access to elective healthcare procedures.
“PatientFi has seen incredible growth over the last few years across the aesthetics market, where market demand is incredibly robust.
“If we can help a practice treat more patients by improving access and keep them coming back, everyone wins,” said Watts.

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Retrieved on:

Wednesday, January 17, 2024

Science, Biotechnology, Research, Pharmaceutical, Health, Cosmetics, Clinical Trials, Retail, Patient, Conference, Safety, Galderma, Botulinum toxin, READY, Pharmaceutical industry

Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously.

Key Points:

Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet), either alone (single-area) or simultaneously.
“We’re looking forward to sharing the latest updates from our world-leading injectable aesthetics portfolio at TOXINS 2024, particularly first data from our phase III READY-3 trial.
READY-3 is a phase III randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy, as measured by aesthetic improvement, of RelabotulinumtoxinA in patients with moderate to severe frown lines or crow’s feet, either administered as a single-area treatment or simultaneously on both frown lines and crow’s feet, when compared to placebo.
Results showed rapid onset of action, with over a third of patients seeing results on day 1 for frown lines (39%) and crow’s feet (34%), and demonstrated long duration of effect for six months.

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Retrieved on:

Tuesday, January 9, 2024

Dupilumab, Culture, Science, Executive Committee, Galderma, GBU, Patient, Head

Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

Key Points:

Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
Paris, January 9, 2024.
Brian Foard, a healthcare industry veteran and Sanofi leader in the U.S., has been named Head of the company’s Specialty Care Global Business Unit (GBU).
With this appointment, which is effective immediately, Brian becomes a member of Sanofi’s Executive Committee.
Brian has been interim Head of the GBU since September 2023 while also serving as Head of Specialty Care North America and U.S. Country Lead.

Bitfarms Appoints Tracy Krumme as Senior Vice President, Head of Investor Relations

Retrieved on:

Monday, January 8, 2024

Bitcoin, DXC Technology, Pullman Company, NCR Corporation, Thermo Fisher Scientific, Sandler, Microsoft, PPD, Partner, Sandler O'Neill and Partners, Research, Prudential Securities, Galderma, Growth, IPO, Senior, Cryptocurrency

TORONTO, Ontario and BROSSARD, Québec, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ: BITF//TSX: BITF), a global vertically integrated Bitcoin mining company, today announced that it has appointed Tracy Krumme as Senior Vice President, Head of Investor Relations.

Key Points:

TORONTO, Ontario and BROSSARD, Québec, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ: BITF//TSX: BITF), a global vertically integrated Bitcoin mining company, today announced that it has appointed Tracy Krumme as Senior Vice President, Head of Investor Relations.
Ms. Krumme has more than 30 years of leadership experience in investor relations, financial communications, investment banking, and equity research.
“In addition to her extensive investor relations and capital markets experience, Tracy has an established reputation among the investment community.
I look forward to engaging with investors and analysts to foster relationships and effectively communicate Bitfarms’ compelling growth story.”

Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines

Retrieved on:

Thursday, November 30, 2023

Pharmaceutical, Health, Clinical Trials, GAIS, Galderma, Patient, Titan IIIB, LCL, Pharmaceutical industry, Botulinum toxin

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).

Key Points:

Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and lateral canthal lines (LCL – crow’s feet).
RelabotulinumtoxinA was well tolerated; the majority of patients did not experience any adverse events and there were no related serious adverse events reported.1
43QM2107 is a phase IIIb, open-label, single-center study to assess aesthetic improvement of RelabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines.
By day two, 100% of patients noted improvement for crow’s feet and 96% noted improvement for frown lines.
For frown line severity, 32% of patients on day one and 92% of patients on day four received a score of zero or one.

Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories

Retrieved on:

Tuesday, November 21, 2023

For the period, net sales growth was strong across all product categories, with balanced contributions across volume, pricing and brand mix.

Key Points:

For the period, net sales growth was strong across all product categories, with balanced contributions across volume, pricing and brand mix.
Internationally, there was particularly strong growth momentum across product categories in fast growing Asian and Latin American markets, including China, India, and Mexico.
Based on the strong performance so far, Galderma is on track to deliver at the upper end of its 6-9% net sales constant currency growth range.
In Dermatological Skincare, Galderma experienced double-digit net sales growth year-on-year over the first nine months of 2023 on a constant currency basis.

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on:

Thursday, November 9, 2023

Orphan drug, Research, CVS Caremark, Carcinoma, Dermatology, Express Scripts, Quarter, Prescription, KOL, Probability, Nevoid basal-cell carcinoma syndrome, NESS, Patient, IQVIA, Pharmaceutical industry, Video game, Optum, Galderma

In the third quarter of 2023, TWYNEO maintained a high recurring base of prescribers compared to the second quarter.

Key Points:

In the third quarter of 2023, TWYNEO maintained a high recurring base of prescribers compared to the second quarter.
According to IQVIA data, there have been over 13,000 prescriptions of EPSOLAY written in the third quarter of 2023 and over 65,000 prescriptions written to date.
Financial Results for the Quarter Ended September 30, 2023
Total revenue in the three months was $0.2 million, which primarily consisted of licensing revenues from Galderma.
General and administrative expenses for the third quarter of 2023 were $1.9 million compared to $1.8 million for the same period in 2022.

PatientFi and Galderma Partner to Offer Monthly Memberships for Aesthetic Treatments with ASPIRE + PRIVI

Retrieved on:

Thursday, November 9, 2023

Technology, Surgery, Payments, Hospitals, Software, Biotechnology, Health, Pharmaceutical, General Health, Galderma, Patient, Human, Pharmaceutical industry

With cost as the biggest barrier to treatment, Galderma and PRIVI are proudly joining forces to offer the aesthetics market a subscription-based membership to help patients achieve and maintain their look while practices are paid in full upfront.

Key Points:

With cost as the biggest barrier to treatment, Galderma and PRIVI are proudly joining forces to offer the aesthetics market a subscription-based membership to help patients achieve and maintain their look while practices are paid in full upfront.
With this breakthrough collaboration, patients can receive recurring treatments with Galderma’s world-class products with a new, more convenient way to pay.
PRIVI seamlessly integrates with ASPIRE, so patients easily accumulate ASPIRE points and rewards.
ASPIRE + PRIVI is the first collaboration of its kind to address the unique market need to overcome cost and increase patient loyalty to practices in an increasingly crowded market.

Medical Spa Expert Sei Tu Bella Aesthetics Joins Exclusive Haute Beauty Network

Retrieved on:

Tuesday, October 31, 2023

NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Heather Merlo, APRN, FNP-C, is a board-certified family nurse practitioner, serving over 15 years in acute care and emergency medicine at Tampa General Hospital, a level 1 trauma center in Tampa, Florida. At seven months pregnant and facing the wall of the pandemic in 2021, Merlo embarked on the transition from corporate world America to women entrepreneurship. Fueled by the desire to balance the life of a Mother and her role as a women entrepreneur, increasing the confidence in women and striving for regenerative medicine and achieving optimal wellness, especially in light of the pandemic, Sei Tu Bella Aesthetics was founded. With no backup plan, Merlo turned her dreams into reality to pursue her love of aesthetic medicine and empower women by providing an emphasis on women's wellness services.

Key Points:

Sei Tu Bella Aesthetics joins Haute Beauty Network as a medical spa expert representing the Tampa, FL market.
Prior to becoming an independent practitioner, she received specialized training in medical aesthetics at AMET and the top leaders in the industry, such as Merz Pharmaceuticals, Galderma, Allergan, Crown Aesthetics, Revive, and Inmode.
As the first Nurse Practitioner-owned MedSpa in the state of Florida to feature the Empower RF platform by Inmode, Sei Tu Bella Aesthetics became Lutz's premiere women's wellness institute.
Learn more about Sei Tu Bella Aesthetics by visiting: https://hauteliving.com/hautebeauty/member/sei-tu-bella-aesthetics/

Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients

Retrieved on:

Thursday, October 26, 2023

Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Prurigo, Nemolizumab, Safety, Prurigo nodularis, Clinical trial, Patient, III, The New England Journal of Medicine, Multimedia, Pharmaceutical industry, Galderma, Medicine

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.

Key Points:

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.
Nemolizumab was well tolerated, and its safety profile was consistent with phase II trial results.1
This press release features multimedia.
Results from the phase III OLYMPIA 2 trial will be submitted to selected health authorities around the world.
To learn more about prurigo nodularis, watch this video from the New England Journal of Medicine.